Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats
Autore:
Harrison, AA; Liem, YTB; Markou, A;
Indirizzi:
Scripps Clin & Res Inst, Dept Neuropharmacol, La Jolla, CA 92093 USA Scripps Clin & Res Inst La Jolla CA USA 92093 col, La Jolla, CA 92093 USA
Titolo Testata:
NEUROPSYCHOPHARMACOLOGY
fascicolo: 1, volume: 25, anno: 2001,
pagine: 55 - 71
SICI:
0893-133X(200107)25:1<55:FCWASR>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
BRAIN-STIMULATION REWARD; PLACEBO-CONTROLLED TRIAL; FORCED SWIMMING TEST; SEROTONERGIC NEURONAL-ACTIVITY; INTRACRANIAL SELF-STIMULATION; PRESYNAPTIC 5-HT1A RECEPTORS; MEDIAN RAPHE NUCLEI; MAJOR DEPRESSION; COCAINE WITHDRAWAL; ANIMAL-MODEL;
Keywords:
drug withdrawal; depression; serotonin; nicotine; amphetamine; intracranial self-stimulation; reward; motivation; fluoxetine; 5-HT1A antagonist; somatic signs; body weight;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
118
Recensione:
Indirizzi per estratti:
Indirizzo: Markou, A Scripps Clin & Res Inst, Dept Neuropharmacol, CVN-7,10550 N Torrey Pines Rd, La Jolla, CA 92093 USA Scripps Clin & Res Inst CVN-7,10550 N Torrey Pines Rd La Jolla CA USA 92093
Citazione:
A.A. Harrison et al., "Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats", NEUROPSYCH, 25(1), 2001, pp. 55-71

Abstract

The symptom of "diminished interest or pleasure" in rewarding stimuli is an affective symptom of nicotine and amphetamine withdrawal, and a core symptom of depression. An operational measure of this symptom is elevation of brain reward thresholds during drug withdrawal. We report here that acute co-administration of fluoxetine, a selective serotonin reuptake inhibitor, and p-MPPI, a serotonin-1A receptor antagonist, alleviated the diminished interest in brain stimulation reward observed during withdrawal from nicotine or amphetamine in vats (i.e., increased reward). By contrast, the same drugcombination treatment did not reduce the somatic signs of nicotine withdrawal indicating symptom-specific neurobiological abnormalities. Surprisingly, the same treatment had opposite effects in control rats where reductions in reward were produced, suggesting that animal models should be based primarily on studying specific deficits that are pathognomic of a psychiatric disorder. The reversal of the affective aspects of drug withdrawal by a treatment that enhances serotonin neurotransmission indicates that decreased serotonergic function may mediate the reward decrements characterizing nicotine and amphetamine withdrawal, and that these symptoms may be homologous toa cave symptom of non-drug-induced depressions. [Neuropsychopharmacology 25:55-71, 2001] (C) 2001 American College of Neuropsychopharmacology Published by Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 21:38:08